Health & Fitness
Fri, February 17, 2012
LOS ANGELES--([ BUSINESS WIRE ])--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims against the Board of Directors of SeraCare Life Sciences, Inc. (aSeraCarea or the aCompanya) (NASDAQ:SRLS) related to the proposed acquisition of the Company by Linden Capital Partners. The transaction is valued at approximately $82 million or $4.00 per share.
The investigation concerns whether the Board of Directors of SeraCare breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into the proposed transaction, and whether the Company has disclosed all material information to shareholders about the transaction. The Company has seen substantial recent growth. Its share price has sky rocketed from $2.64 on October 4, 2011 to $3.58 on February 10, 2012. Further, at least one analyst has set a target price for the Companyas stock at $5.00.
If you are a shareholder of SeraCare, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067, by telephone at (310) 201-9150 or Toll Free at (888) 773-9224 or by email to [ shareholders@glancylaw.com ].
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
